Abstract
The mechanisms underlying reprogramming of growth factor signaling and metabolic pathways during bone metastasis of breast cancer are not clear. The Runt-related transcription factor (Runx2) regulates cell signaling during mammary epithelial morphogenesis and promotes invasion; therefore, we investigated its role in cell growth and metabolic signaling in bone-seeking breast cancer cells. We performed systemic inoculation of control or Runx2 knockdown invasive MDA-MB-231 cells in NOD/SCID mice, and compared parental and bone-derived variants for phenotypic and molecular alterations. The Runx2 knockdown showed early (0–2 weeks) inhibition of metastatic spread but late (4–6 weeks) outgrowth, suggesting Runx2-dependent bi-phasic response and reprogramming of metastatic cells. The late-stage tumor outgrowth of bone-derived Runx2 knockdown cells was associated with increased insulin-like growth factor- 1Rβ (IGF-1Rβ) levels. Interestingly, glucose uptake and glycolysis were reduced in the bone-derived Runx2 knockdown cells that could be further reduced by extracellular-regulated protein kinase (Erk1/2) inhibition. Furthermore, the Runx2 knockdown cells displayed activation of AMP-activated protein kinase (AMPKα), the sensor of cellular metabolism. Importantly, the Runx2 knockdown in bone-derived cells resulted in increased sensitivity to both Erk1/2 inhibition and AMPKα activation by PD184161 and metformin, respectively, despite increased IGF-1Rβ and AMPKα levels. Our results reveal that Runx2 promotes metastatic spread of mammary tumor cells. The growth of late-stage tumor cells can be targeted by Runx2 knockdown in combination with Mek-Erk1/2 inhibition and metformin treatment.
Similar content being viewed by others
Introduction
Bone metastasis is associated with ~70% mortality in the advanced stages of breast cancer patients and reduction in quality of life.1, 2 During metastasis, the invasive breast cancer cells survive in the bone microenvironment due to pre-existing or acquired changes in cell signaling and metabolic pathways;3, 4, 5, 6, 7 however, underlying regulatory mechanisms are still unknown.
The Runt-related transcription factor (Runx2), a critical factor for bone development,8 is also aberrantly expressed in cancer cells compared with normal mammary epithelial cells,9 where it regulates β-casein,10 osteopontin,11 sialoprotein,12 calcitonin and RANKL.13 Ectopic expression of Runx2 disrupts mammary acini formation in the three-dimensional (3D) culture model and Runx2 transgenic mice display alveolar hyperplasia, ductal carcinoma in situ and age-dependent preneoplastic changes.14, 15 In breast cancer patient specimens, Runx2 expression levels correlated to triple negative tumor status and poor clinical outcome.15, 16 Intriguingly, Runx2 suppresses proliferation of osteoblasts, and functions in both tumor suppressor-related and oncogene-related properties of breast and osteosarcoma cells.17, 18, 19 These studies suggest context-dependent functions of Runx2 in cancer progression. However, the role of Runx2 in initial colonization and growth of tumor cells during bone metastasis is still unclear.
The bone microenvironment is conducive for tumor survival because it harbors several growth factors,20 including insulin-like growth factors (IGFs). IGF-1, a potent mitogen, activates IGF-1Rβ receptor tyrosine kinase during bone metastasis.21 The activation of IGF-1Rβ triggers downstream signaling including the PI3K/Akt pathway, a critical driver of tumor growth.22 The IGF-1Rβ levels are increased in breast cancer metastasis and disruption of IGF-1/IGF-1R signaling inhibited tumorigenesis in preclinical models.22, 23, 24, 25 In addition to increased growth factor signaling, the tumor cells undergo metabolic reprogramming by altering glucose uptake or glycolysis.26 Our previous studies and other reports demonstrated regulatory roles of Runx2 in growth factor signaling,27 tumor cell migration28, 29 and survival during glucose deprivation.9 However, Runx2-dependent crosstalk between growth factor and metabolic signaling pathway in bone metastasis is still unclear. Here we demonstrate Runx2-mediated IGF-1Rβ-pAkt and AMPK-Erk1/2 (extracellular-regulated protein kinase) signaling crosstalk in survival of bone-derived breast cancer cells. Importantly, Runx2 knockdown sensitizes these cells for Mek-Erk1/2 inhibition and metformin treatment.
Results
Runx2 knockdown inhibits early metastatic spread but promotes late-stage tumor regrowth in bone
To determine the role of Runx2 in mammary tumor metastasis, we stably knockdown Runx2 in high endogenous Runx2 expressing invasive MDA-MB-231 cells.9 We observed up to 80% Runx2 suppression (Supplementary Figures S1A and B) and consistent with the previous results,7, 28, 30 the Runx2 knockdown resulted in delay in wound healing response indicating a positive role of Runx2 in cell migration (Supplementary Figure S1C). Next, we systemically inoculated luciferase-expressing control or Runx2 knockdown cells in NOD/SCID mice via intra-cardiac route and quantified the metastatic outgrowth by bioluminescence imaging (Figure 1a). The Runx2 knockdown cells showed an early decline (week 1, 45%, P<0.05 and week 2, 36%, P<0.1) in overall metastatic outgrowth compared with the control cells (Figure 1b). However, at later time (weeks 4–6), the Runx2 knockdown cells showed significantly upregulated (week 4, 75%, P<0.05; week 5, 60%, P<0.05 and week 6, 36%, P<0.1) overall metastatic outgrowth (Figure 1b). No significant differences were noted at week 3, suggesting a shift in growth rate of Runx2 knockdown cells. These results could not be accounted due to differences in the luciferase expression among these cells (Supplementary Figure S1D). Although tumor growth was observed in multiple sites including brain, liver and kidney, we stratified the overall bioluminescence signal to lungs and bones, the most common sites of breast cancer metastasis (Supplementary Figure S1E). The bone metastasis incidences were nearly doubled and tumor growth in bone was observed in the Runx2 knockdown group at later time point (Supplementary Figures S1F and G). For lung metastasis, Runx2 knockdown showed 40% reduced incidences with a modest twofold increase in tumor growth. To determine the tumor growth associated bone loss, we performed X-ray and microcomputed tomography (μCT) analysis on long bones (femur and tibia). These analyses revealed that late-stage regrowth of Runx2 knockdown cells are associated with osteolytic lesions in proximal tibia and cortical bone loss (Figure 1c and Supplementary Figure S1H). To quantify the bone loss, we performed 3D rendering of the trabeculae distal to the growth plate in proximal tibia by μCT. This analysis indicated that trabecular bone volume fraction and connectivity was significantly reduced in the Runx2 knockdown group compared with controls (Figure 1d and Supplementary Figure S1I). Taken together, these results suggest a bi-phasic role of Runx2 during tumor metastasis, wherein Runx2 loss delays tumor cell migration, metastasis at early (1–2 weeks) stages, while it enhances tumor growth in bone and osteolysis at later stages (4–6 weeks).
Bone-derived Runx2 knockdown cells show increased IGF-1Rβ expression levels
To understand the role of Runx2 in late-stage metastatic outgrowth in bones, we investigated the growth factor receptor signaling. To achieve this, we isolated these tumor cells from mice 6 weeks post-injection, and compared tumor-derived and parental cells to determine alterations in growth factor receptor signaling. The IGF-1Rβ expression levels were significantly upregulated in bone-derived Runx2 knockdown cells compared with matched bone-derived control cells (Figure 2a, right). In contrast, the epidermal growth factor receptor levels were reduced (20–50%) in lung or bone-derived cells (Supplementary Figure S2A). Furthermore, IGF-1Rβ levels were similar in parental population or lung-derived Runx2 knockdown cells, suggesting that increased IGF-1Rβ levels could specifically facilitate late-stage tumor growth in bone due to loss of Runx2. To determine the activity of IGF-1Rβ signaling pathway, the serum-deprived cells were stimulated with IGF-1. The basal levels of IGF-1Rβ phosphorylation (pIGF-1Rβ) in serum-deprived conditions were either undetectable or present in low levels and were reduced in bone-derived Runx2 knockdown cells. As expected, the IGF-1 stimulation for 1 h showed potent and dose-dependent induction of pIGF-1Rβ and downstream pAkt in both parental and bone-derived Runx2 knockdown or control cells (Figures 2b and c, upper panels). Importantly, the bone-derived Runx2 knockdown cells showed prolonged (⩾6 h) pIGF-1Rβ and pAkt levels upon IGF-1 stimulation compared with control or parental cells (Figures 2b and c, lower panels). We observed variation in total IGF-1Rβ levels upon IGF-1 treatment at various time points examined that could be related to receptor internalization and turnover.31 However, the bone-derived Runx2 knockdown cells displayed higher total IGF-1Rβ levels compared with control cells at every time point examined. Consistent with membrane localization,22 we also observed that pIGF-1Rβ was predominantly localized at cell boundaries (Figure 2d). Next, to determine if the increase in pAkt levels are dependent upon IGF-1-mediated pIGF-1Rβ expression levels or crosstalk with the Mek-Erk1/2 pathway,27 we utilized OSI-906 (Linsitinib), LY294002 and PD184161, selective inhibitors of pIGF-1Rβ, PI3K/Akt and Mek-Erk1/2 signaling, respectively. Indeed, the IGF-1-mediated induction of pIGF-1Rβ and pAkt levels in bone-derived Runx2 knockdown cells was completely abrogated by OSI-906 treatment confirming that pAkt induction is dependent upon IGF-1-mediated pIGF-1Rβ (Figure 2e). Additionally, LY294002 treatment reduced pAkt levels suggesting that PI3K activity is required for IGF-1Rβ-induced pAkt, while PD184161 treatment increased pAkt levels (Figure 2f). Finally, to validate that bone microenvironment enhanced IGF-1Rβ levels and downstream signaling upon Runx2 depletion, we examined IGF-1Rβ levels in non-bone-derived and bone-derived cancer cell lines. The Runx2 knockdown in bone-derived control MDA-MB-231 cells (Figure 2g) and prostate cancer PC3 cell line, but not in breast carcinoma-derived Hs578t cells (Supplementary Figure S2B) showed increased pIGF-1Rβ levels upon IGF-1 treatment at various time points. The reinoculation of Runx2 knockdown cells in ex vivo bone co-cultures (Supplementary Figure S3A) showed further increased pIGF-1Rβ levels compared with bone-derived cells (Figure 3a). Interestingly, the IGF-1Rβ mRNA levels were not altered significantly with Runx2 knockdown (Supplementary Figure S3B). Furthermore, the Runx2 knockdown in bone-derived MDA-MB-231 cells was not affected by IGF-1 or inhibitor treatments (Supplementary Figure S3C). Altogether, these results show that the late-stage metastatic outgrowth of Runx2 knockdown cells in bone is associated with increased IGF-1Rβ signaling.
Bone-derived Runx2 knockdown cells show reduced Erk1/2 levels and altered expression of IGF-1Rβ pathway genes
Previously, we and others have demonstrated that crosstalk between Mek-Erk1/2 and PI3K-Akt pathways upregulates growth factor receptor levels in mammary epithelial cells.27, 32 Furthermore, consistent with our previous findings,9 our results show increased pAkt levels upon Mek inhibitor PD184161 treatment (Figure 2f). Therefore, we determined endogenous Erk1/2 levels and downstream target genes of IGF-1Rβ/Akt signaling. The total and pErk1/2 levels were reduced in bone-derived Runx2 knockdown cells (Figures 3a and b). Next, to determine whether altered pErk1/2 and IGF-1Rβ levels are due to clonal selection, we examined single-cell-derived colonies isolated from both parental and bone-derived MDA-MB-231 populations. These colonies showed varying expression levels of pErk1/2, pIGF-1Rβ and total IGF-1Rβ (Figure 3c). The quantification of the expression level of these proteins in six clones revealed reduced pIGF-1Rβ and total IGF-1Rβ levels in Runx2 knockdown parental cells compared with control (Figure 3d). Importantly, colonies from Runx2 knockdown bone-derived cells displayed variable and reduced pErk1/2 but increased pIGF-1Rβ levels compared with control cells (Figures 3c, lower panel and d). These results suggest that the increase in pIGF-1Rβ/pAkt signaling in bone-derived cells is not due to selection of a clonal population in bone.
To determine the expression levels of downstream target genes of the IGF-1Rβ pathway, we analyzed pathway-related genes in a PCR array and compared bone-derived Runx2 knockdown cells with control and parental cells. We identified eight genes showing ⩾2-fold upregulation including c-Fos that showed a sevenfold increase (Figure 3e). We validated the array data by utilizing alternate primer sets in reverse transcriptase–PCR and western blot analysis (Figures 3f and g). The induction of c-Fos is consistent with the IGF-1/IGF-1Rβ-responsive differential gene expression changes that facilitate cancer progression.33 Additionally, expression of other PI3K/Akt signaling target genes such as apoptosis inhibitor Bcl2l1 and genes linked to fatty acid and cholesterol metabolism (ACACA, FASN, LDLR, SREBF1) was reduced in bone-derived Runx2 knockdown. Taken together, our results show that increased pIGF-1Rβ/pAkt signaling and altered expression of IGF-1Rβ responsive genes in Runx2 knockdown cells are associated with Erk1/2 downregulation.
Increased IGF-1Rβ and reduced Erk1/2 expression levels in bone-derived Runx2 knockdown cells are due to loss of β-Arrestin-1/2 expression
To understand how IGF-1Rβ and Erk1/2 expression levels are coupled to loss of Runx2 in bone-derived cells, we examined the levels of β-Arrestins, downstream adapter proteins that promote IGF-1Rβ internalization and ubiquitination.34 The β-Arrestin-1/2 gene expression was reduced by fivefold and nearly 50–75% reduction in protein expression was observed in bone-derived Runx2 knockdown cells compared with control and parental cells (Figures 4a–c). The decline in β-Arrestin-1/2 was not affected by stimulating or inhibiting IGF-1Rβ or Erk1/2 signaling (Figure 4d). Therefore, to determine whether Runx2 regulates β-Arrestin-1/2 expression, a β-Arrestin-1 promoter fragment (+250 bp) containing putative Runx-binding sequences was cloned upstream of luciferase reporter (Supplementary Figure S4). The overexpression of WT-Runx2 in MDA-MB-231 or HeLa cells showed nearly twofold increase in luciferase reporter activity (Figures 4e and f). The HeLa cells were included in this analysis because these cells lack endogenous Runx2.35 Since β-Arrestin-1/2 expression was substantially reduced only in bone-derived Runx2 knockdown cells but not in parental cells, we tested a possibility of epigenetic regulation of β-Arrestin-1/2 in bone-derived cells. First, we examined the global histone acetylation levels and found that acetylation of Histone H3 (lysine 9) was reduced by 30% in bone-derived Runx2 knockdown cells (Figure 4g). Second, we tested whether treatment of bone-derived cells with Trichostatin A, a selective inhibitor of histone deacetylases and activator of histone H3 acetylation, rescues the β-Arrestin-1/2 gene expression. Indeed, the Trichostatin A treatment in bone-derived Runx2 knockdown cells elevated the β-Arrestin-1/2 gene expression level comparable to control cells (Figure 4h). Furthermore, the Trichostatin A treatment reduced total IGF-1Rβ levels in bone-derived Runx2 knockdown cells to the level of control cells (Figures 4i and j). Altogether, these results suggest that combination of decreased acetylation and loss of Runx2 reduces β-Arrestin-1/2 expression and increases IGF-1Rβ protein levels. Finally, to genetically validate these results, we overexpressed rat β-Arrestin-1 in bone-derived MDA-MB-231 cells. The β-Arrestin-1 overexpression reduced IGF-1Rβ and increased Erk1/2 levels (Figure 4k). These results confirm that Runx2 inhibits IGF-1Rβ levels and increases Erk1/2 expression by regulating β-Arrestin-1/2.
Runx2 knockdown increases sensitivity towards pharmacologic Erk1/2 inhibition
The altered levels of pIGF-1Rβ and pErk1/2 proteins in bone-derived Runx2 knockdown cells led to the hypothesis that these cells may be susceptible to targeting kinase activity. Therefore, we treated these cells with pharmacologic inhibitors and examined cell viability. The PD184161 treatment, but not OSI-906 or LY294002, showed loss of cell viability in MTT assays in both parental and bone-derived cells and was independent of Runx2 levels (Figure 5a, left and center panel). Since Runx2 knockdown reduced pErk1/2 levels (Figures 3a–d), we next tested sensitivity of these cells to lower doses of PD184161. The PD184161 treatment in bone-derived Runx2 knockdown cells showed more than twofold reduction in MTT absorbance after 48 h, while the hemocytometer cell counts were minimally reduced or unchanged compared with control cells (Figure 5a, right panel and Supplementary Figure S5A). These results suggested that metabolism could be altered in Runx2 knockdown cells since MTT is based on bio-reduction of tetrazolium compound and reflects the rate of glycolytic NADH production in metabolically active cells.36
Since MDA-MB-231 cells are predominantly glycolytic,37, 38 we next tested Runx2-dependent changes in metabolism by measuring glucose uptake and glycolytic capacity. The Runx2 knockdown cells revealed lower glucose uptake in both parental and bone-derived cells compared with controls (Figure 5b). Although, glycolysis, as indicated by the extracellular acidification rate, was reduced in bone-derived cells, no Runx2-dependent changes were observed (Figure 5c, left). However, treating bone-derived Runx2 knockdown cells with PD184161 resulted in significant reduction of extracellular acidification rate (Figure 5c, right). Next, we determined phenotypic changes after long-term pharmacologic IGF-1Rβ and Erk1/2 inhibition. The bone-derived Runx2 knockdown cells treated with OSI-906 showed reduced colony size compared with vehicle-treated controls (Figure 5d), while treatment with PD184161 resulted in no colony formation or anchorage-independent cell growth (Figure 5e). Taken together, these results suggest that long-term pharmacologic IGF-1Rβ inhibition can reduce cell growth but not survival and that can be effectively targeted by inhibition of the Mek-Erk1/2 pathway.
Runx2 knockdown potentiates metformin-induced energy metabolism and inhibition of cell viability
To understand how Runx2 knockdown cells survive in bone microenvironment despite reduced glucose uptake and glycolysis, we examined adaptive modifications in regulation of energy metabolism. The AMP-activated protein kinase (AMPKα) is a ubiquitous regulator of energy homeostasis and its phosphorylation is triggered by glucose stress or hypoxia in tumor microenvironment.39 The basal levels of pAMPKα were higher (2.8-fold) in bone-derived Runx2 knockdown cells compared with control (Figures 6a and b), suggesting that these cells are responding to metabolic stress. The increase in pAMPKα levels persisted in the presence of IGF-1 or insulin treatment (Figure 6c), while the total AMPKα protein levels were not significantly altered with Runx2 knockdown (Supplementary Figure S5B). It has been suggested that the extent and duration of AMPKα activation could induce growth arrest or cell death.40 Therefore, to examine whether further increase in pAMPKα levels promote cell death, we treated these cells with metformin. Previous studies have shown potent antiproliferative effects of metformin via AMPKα activation and Erk1/2 inhibition in triple negative cell lines.41, 42, 43 We reasoned that Runx2 knockdown in bone-derived cells showing high pAMPKα and low Erk1/2 should potentiate the metabolic and growth inhibitory effects of metformin. The metformin treatment in bone-derived MDA-MB-231 cells resulted in further increase in pAMPKα levels and decrease in Erk1/2 levels in Runx2 knockdown cells (Figures 6d–f and Supplementary Figures S5C and D). Notably, Runx2 knockdown in bone-derived cells showed reduced p-p70S6K in basal and metformin-treated conditions compared with control cells. The selective AMPK inhibitor Compound C44 mitigated pAMPKα activation and p-p70S6K reduction. Furthermore, metformin treatment reduced the IGF-1Rβ levels in bone-derived Runx2 knockdown cells in dose- and time-dependent manner (Figure 6g) coupled with significant cellular rounding, cytoskeletal condensation and reduced cell growth (Figure 6h). Consistently, the increase in p-p70S6K has been shown to decrease cell circularity and promote adhesion.45 At various doses (0.2–5 mm), metformin treatment did not show Runx2-dependent effect on cell proliferation (Supplementary Figure S5A); however, significantly reduced metabolism was observed in bone-derived Runx2 knockdown cells (Figure 6i) as determined by MTT assays. The reduction in β-Arrestin-1/2 levels was not affected by metformin treatment in these cells (Figures 6e and f). Therefore, the decline p-p70S6K and increase in pAMPKα suggest that Runx2 knockdown induces stress response in metastatic cells. Altogether, our results in bone-derived MDA-MB-231 cells indicate that loss of Runx2 potentiates the effect of AMPKα activation or Mek-Erk1/2 inhibition in regulating tumor cell metabolism and growth.
Discussion
We identified a novel regulatory function of Runx2 that integrate IGF-1Rβ/Akt and AMPKα/Erk signaling crosstalk in growth of bone-derived metastatic breast cancer cells (Figure 7). The bone microenvironment provides enriched growth factor environment;4, 46, 47 however, the signaling response of metastatic cancer cells to these conditions in bone is still unclear. Here, we characterized bone-derived MDA-MB-231 cells after systemic inoculation of parental population. We found that Runx2 loss delays early metastatic spread of these cells. The late-stage growth of Runx2 knockdown cells is associated with activation of IGF-1Rβ and AMPKα signaling. Importantly, Runx2 loss sensitizes bone-derived MDA-MB-231 cells to Mek-Erk1/2 inhibition and metformin treatment. Our results highlight Runx2 as a potential therapeutic target in combination with metformin or Mek-Erk1/2 inhibitors for bone metastasis.
The ligand IGF-1 from bone matrix binds and activates IGF-1Rβ to promote tumor cell survival and growth.48, 49 Our results show that the total IGF-1Rβ level increases due to reduced β-Arrestin-1/2 in Runx2 knockdown bone-derived MDA-MB-231 cells, and prolongs IGF-1Rβ/Akt signaling upon IGF-1 stimulation compared with parental cells (Figure 2). Previously, we showed that Runx2 loss in parental MDA-MB-231 cells reduces mTORC2 and diminishes epidermal growth factor-dependent Akt activation.9 Since Akt is one of the central node of multiple growth factor signaling and glucose metabolism,50 our results suggest that Runx2 levels are important to balance growth factor signaling depending upon microenvironment and metabolic status of cancer cells.
The clinical trials targeting IGF-1R have not achieved desired outcome,51 presumably due to lack of patient stratification or resistance to small molecules. We show that blocking the activity of Mek-Erk1/2, but not IGF-1Rβ, inhibits survival of high IGF-1Rβ-expressing Runx2 knockdown bone-derived MDA-MB-231 cells (Figures 5d and e). Our results demonstrate that despite increased IGF-1Rβ signaling, the bone-derived Runx2 knockdown cells were sensitive for pharmacologic Mek inhibition, and thus indicating their dependency on Mek-Erk1/2 pathway for survival. Taken together, our results suggest that tumors with high IGF-1R signaling may be effectively targeted by the Mek-Erk1/2 pathway inhibitors.
The Runx2-mediated regulation of target genes depends on its co-regulatory complex.52 We show that the Runx2-β-Arrestin-1/2 axis operates in bone derived but not in parental MDA-MB-231 cells. The differential regulation of β-Arrestin-1/2 could be due to altered Runx2 co-regulatory complex53 via post-translational modifications of Runx254, 55 or epigenetic regulation of β-Arrestin promoter. In addition to Runx2, glucocorticoids have been shown to differentially regulate β-Arrestin-1/2 gene expression.56 The decline in acetylated histone H3 in bone-derived Runx2 knockdown cells indicated epigenetic change that could alter β-Arrestin regulation. These epigenetic changes could be due to context-dependent activity of histone deacetylases and Runx2. Previous reports indicate that Runx2 not only physically interacts with epigenetic regulators such as (HDAC-1, HDAC-6, p300)57, 58, 59, 60, 61 but can also regulate transcription of methyl transferases (e.g., Ezh2),62 thereby altering histone modification. The treatment with Trichostatin A, an inhibitor of histone deacetylase activity, in bone-derived Runx2 knockdown cells restored the loss of β-Arrestin-1/2 expression (Figure 4h). Furthermore, Runx2 activity is affected by post-translational modifications such as phosphorylation on serine and threonine residues, acetylation and sumoylation as shown in osteoblastic lineage cells,55, 63, 64 prostate cancer cell lines and patient samples.65 Taken together, these reports suggest context-dependent roles of Runx2 via post-translational modifications during metastasis.
Runx2 functions at various stages of tumor progression as highlighted by several xenograft or genetic mouse models. The Runx2 overexpressing transgenic mice showed age-related preneoplastic changes in mammary epithelium.15 Direct tibial inoculation of MDA-MB-231 cells with Runx2 knockdown (2 weeks) or miRNAs targeting Runx2 (4 weeks) showed reduced tumor growth and osteolysis.28, 66 The ectopic Runx2 expression in bone metastatic prostate cancer PC3 cells increased tumor growth when examined for 2 weeks.65 Consistent with these studies, systemic inoculation of Runx2 knockdown cells showed delayed metastatic tumor growth at early time points (2 weeks) in our study. The reduction in tumor growth in the Runx2 knockdown group was compensated at later time points as these cells displayed regrowth in bone due to increased IGF-1Rβ. The results from these in vivo studies suggest that the route of cell injections, gene delivery method, tumor growth in visceral organs and bones, and the time required to reach the critical tumor size for osteolysis may contribute to Runx2 response in tumor growth. Furthermore, these results highlight stage-specific adaptation of metastatic cancer cells in bone microenvironment via activation of IGF-1Rβ and AMPKβ signaling. The adaptation of cancer cells in metastatic microenvironment can be affected by the extent of AMPKα activation.40 The increase in basal pAMPKα with Runx2 knockdown (Figures 6a–c) could allow bone-seeking cells to cope with stress and increase survival, as also seen in other cancer types during nutrient-deprivation conditions.67, 68 However, further increase in magnitude and duration of AMPKα activation by metformin could inhibit cell proliferation, cell cycle and survival.42, 43, 69, 70 Consistent with these results, we observed reduced viability of Runx2 knockdown cells with metformin treatment. Metformin indirectly promotes pAMPK by inhibiting complex I of the electron transport chain and increases AMP levels relative to ATP.71, 72 The increased pAMPKα levels in bone-derived Runx2 knockdown cells (Figures 6a–c) suggest altered AMP/ADP levels relative to ATP due to reduced glucose uptake (Figure 5b). The gene expression of LKB1, a serine/threonine kinase of AMPKα 73 and total AMPKα protein levels did not change significantly in Runx2 knockdown cells (data not shown and Supplementary Figure S5B) further support the indirect role of Runx2 on pAMPKα regulation. Importantly, our results demonstrating metformin-mediated potent reduction in IGF-1Rβ and Erk1/2 levels in bone-derived Runx2 knockdown cells indicate antitumor growth effects of metformin. Taken together, our results support targeting growth factor and metabolic signaling crosstalk using combinatorial approaches and repositioning of metformin for breast cancer bone metastasis.
Materials and methods
Cell lines, vectors and chemicals
The sources are listed in the supplementary section (Supplementary Table ST1). The MDA-MB-231, Hs578t and PC3 cells were cultured in minimum essential medium supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. For IGF-1 treatment, the cells were first serum deprived (0.25%) for 16 h. In experiments requiring, IGF-1Rβ inhibitor OSI-906/Linsitinib, PI3K inhibitor LY294002, Mek inhibitor UO126 or PD184161 treatment, the serum-deprived cells were pretreated with inhibitors for 10 min. The metformin was treated in serum- and glucose-deprived (100 mg/l) media.
The cell lines stably expressing Runx2 shRNA (Runx2-RNAi), WT-Runx2, firefly luciferase (Luc) and green fluorescent protein were generated utilizing lentivirus vectors.14 The rat pcDNA3.1-β-Arrestin-1 expression plasmid was obtained from Addgene (Cambridge, MA, USA)74 and transfected with lipofectamine LTX reagent, while pcDNA3 served as a vector control.
Bioluminescence imaging
All protocols were approved by RUSH University Medical Center Animal Care and Use committee. The six-week-old female NOD/SCID mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). MDA-MB-231 cells (105/100 μl) were inoculated intracardiacally into isoflurane anesthetized mice (10/group).75, 76 The mice were excluded from the study based on any sign of distress or infection. The tumor growth was weekly monitored by bioluminescence imaging (IVIS/Lumina; PerkinElmer, Waltham, MA, USA). The anesthetized mice were intraperitoneally inoculated with d-luciferin (3 mg/20 g) and the luminescent image was acquired. The region of interest was analyzed in a blinded manner using Living Image 4.1 software (PerkinElmer). To confirm the tumor location, mice were killed after 6 weeks, and organs were dissected and bioimaged. The experiments were repeated twice.
Radiography and μCT
The dorso-ventral radiographs were obtained using MX-20; Faxitron X-ray machine (Lincolnshire, IL, USA) at 20kV for 10 s. The designated bones (tibia and femur) were preserved in 10% formalin and stored in phosphate-buffered saline for μCT and histomorphometry. The μCT evaluation was performed in a blinded manner at Rush University’s Histology Core Services.77 The trabecular bone architecture parameters (bone volume fraction and trabecular connectivity) were obtained from the proximal tibia growth plate region.
Isolation of tumor cells
The tibia, femur and vertebrae were obtained from mice displaying osteolytic lesions. The cells were aseptically aspirated from bone marrow using a 28G needle. The vertebrae and lung were sliced, and incubated in collagenase and hyaloronidase containing growth media for 2 h. The cells were subsequently washed with phosphate-buffered saline, centrifuged and seeded. The fluorescence-activated cell sorting (green fluorescent protein) was performed at University of Illinois at Chicago. The single-cell colonies were isolated from 103 cells by performing serial 10-fold dilution. A 100 μl suspension of single cells was seeded on a 96-well plate and expanded.
Ex vivo tumor-bone co-culture
The tibia and femur were aseptically dissected and the proximal end was excised to reveal marrow cavity. The control or Runx2 knockdown MDA-MB-231 cells (2 × 104/10 μl) in serum-free media were inoculated into marrow using a 291/2G needle. The bones with tumor cells were incubated for 2 weeks and bioimaged.
Western blotting and immunofluorescence
The western blot and immunofluorescence analysis were performed as previously described.9, 27 The antibodies are listed in Supplementary Table ST1.
Real-time PCR
The real-time PCR analysis was performed as previously described.9 The primers (IDT, Coralville, IA, USA) are listed in Supplementary Table ST1. A human insulin pathway responsive PCR array was obtained from SA Biosciences (Qiagen, Valencia, CA, USA).
Luciferase assay
The TF search database was used to identify Runx-binding sites on β-Arrestin-1 promoter.78 The WT or mutant β-Arrestin-1 promoters (+1–250 bp) were cloned in pcDNA3.1. The Runx2-binding consensus sequences, CA79 were replaced by ‘T’ or ‘G’ in the mutant promoter (Supplementary Figure S4). The firefly and renilla luciferase plasmids were transfected using lipofectamine LTX and dual luciferase reporter assay (Promega, Madison, WI, USA) was performed.
Cell viability assay
The cell viability was determined by MTT assay (Promega) as previously described.9
In vitro clonogenic and soft agar assay
The clonogenic assays were performed by seeding 500 cells in a 100 mm dish for 12 days and colonies were stained with crystal violet (0.5 in 25% methanol). For soft agar assay, 5000 cells were plated in 0.35% agarose in growth media on top of solidified agarose (0.5%). The growth media was replaced every 3 days for 3 weeks.
Glucose uptake and glycolysis
The colorimetric glucose uptake assay was performed according to the manufacturer’s guidelines (Sigma, St Louis, MO, USA). The glycolysis was determined as the extracellular acidification rate in response to glucose treatment in an XF-24 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA, USA). The MDA-MB-231 cells (4 × 104) were seeded in 96-well plates and serum-deprived overnight. The cells were rinsed with phosphate-buffered saline and incubated in glucose-free XF-assay medium. Subsequently, the cells were sequentially treated with glucose (10 mm), oligomycin (10 μm) and 2-DG (10 mm) in the analyzer and extracellular acidification rate values were recorded.
Statistical analysis
The data were analyzed by unpaired Student's t-test. P≤0.05 and P≤0.1 were considered as significant or marginally significant, respectively.
References
Coleman RE, Rubens RD . The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55: 61–66.
Ibrahim T, Mercatali L, Amadori D . A new emergency in oncology: bone metastases in breast cancer patients (Review). Oncol Lett 2013; 6: 306–310.
Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 2004; 64: 4506–4513.
Mundy GR . Mechanisms of osteolytic bone destruction. Bone 1991; 12 (Suppl 1): S1–S6.
Chambers AF, Groom AC, MacDonald IC . Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563–572.
Kingsley LA, Fournier PG, Chirgwin JM, Guise TA . Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609–2617.
Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ et al. Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol 2013; 228: 1784–1792.
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755–764.
Tandon M, Chen Z, Pratap J . Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells. Breast Cancer Res 2014; 16: R16.
Inman CK, Li N, Shore P . Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 2005; 25: 3182–3193.
Inman CK, Shore P . The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 2003; 278: 48684–48689.
Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ et al. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 2003; 63: 2631–2637.
Martin TJ, Gillespie MT . Receptor activator of nuclear factor kappa B ligand (RANKL): another link between breast and bone. Trends Endocrinol Metab 2001; 12: 2–4.
Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J et al. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: implications for breast cancer progression. Cancer Res 2009; 69: 6807–6814.
McDonald L, Ferrari N, Terry A, Bell M, Mohammed ZM, Orange C et al. RUNX2 correlates with subtype-specific breast cancer in a human tissue microarray, and ectopic expression of Runx2 perturbs differentiation in the mouse mammary gland. Dis Model Mech 2014; 7: 525–534.
Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010; 101: 2670–2675.
Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 2003; 63: 5357–5362.
Lucero CM, Vega OA, Osorio MM, Tapia JC, Antonelli M, Stein GS et al. The cancer-related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol 2013; 228: 714–723.
Chimge NO, Frenkel B . The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 2013; 32: 2121–2130.
Roodman GD . Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655–1664.
Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y et al. Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res 2012; 72: 4238–4249.
Riedemann J, Macaulay VM . IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13 (Suppl 1): S33–S43.
Arteaga CL . Interference of the IGF system as a strategy to inhibit breast cancer growth. Breast Cancer Res Treat 1992; 22: 101–106.
Dunn SE, Ehrlich M, Sharp NJ, Reiss K, Solomon G, Hawkins R et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998; 58: 3353–3361.
Sachdev D, Zhang X, Matise I, Gaillard-Kelly M, Yee D . The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival. Oncogene 2010; 29: 251–262.
Boroughs LK, DeBerardinis RJ . Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 2015; 17: 351–359.
Tandon M, Chen Z, Pratap J . Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells. J Cell Biochem 2014; 115: 2208–2217.
Taipaleenmaki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res 2015; 75: 1433–1444.
Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS et al. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells. Mol Cancer 2012; 11: 27.
Leong DT, Lim J, Goh X, Pratap J, Pereira BP, Kwok HS et al. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 2010; 12: R89.
Monami G, Emiliozzi V, Morrione A . Grb10/Nedd4-mediated multiubiquitination of the insulin-like growth factor receptor regulates receptor internalization. J Cell Physiol 2008; 216: 426–437.
Aksamitiene E, Kiyatkin A, Kholodenko BN . Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 2012; 40: 139–146.
Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002; 4: 204–217.
Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ . Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways. Dev Cell 2009; 17: 443–458.
Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005; 25: 8581–8591.
Berridge MV, Herst PM, Tan AS . Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11: 127–152.
Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ . Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 2005; 7: 324–330.
Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ . Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008; 10: 745–756.
Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J et al. 5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006; 26: 5336–5347.
Liang J, Mills GB . AMPK: a contextual oncogene or tumor suppressor? Cancer Res 2013; 73: 2929–2935.
Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8: 2031–2040.
Zhuang Y, Miskimins WK . Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008; 3: 18.
Zordoky BN, Bark D, Soltys CL, Sung MM, Dyck JR . The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: implications for cancer therapy and prevention. Biochim Biophys Acta 2014; 1840: 1943–1957.
Liu X, Chhipa RR, Nakano I, Dasgupta B . The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 2014; 13: 596–605.
Henkels KM, Mallets ER, Dennis PB, Gomez-Cambronero J . S6K is a morphogenic protein with a mechanism involving Filamin-A phosphorylation and phosphatidic acid binding. FASEB J 2015; 29: 1299–1313.
Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP et al. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010; 21: 951–960.
Suva LJ, Washam C, Nicholas RW, Griffin RJ . Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011; 7: 208–218.
Guise T . Examining the metastatic niche: targeting the microenvironment. Semin Oncol 2010; 37 (Suppl 2): S2–S14.
Xian L, Wu X, Pang L, Lou M, Rosen CJ, Qiu T et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med 2012; 18: 1095–1101.
Taniguchi CM, Emanuelli B, Kahn CR . Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006; 7: 85–96.
Yee D . Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104: 975–981.
Thirunavukkarasu K, Mahajan M, McLarren KW, Stifani S, Karsenty G . Two domains unique to osteoblast-specific transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta. Mol Cell Biol 1998; 18: 4197–4208.
Westendorf JJ . Transcriptional co-repressors of Runx2. J Cell Biochem 2006; 98: 54–64.
Franceschi RT, Ge C, Xiao G, Roca H, Jiang D . Transcriptional regulation of osteoblasts. Cells Tissues Organs 2009; 189: 144–152.
Jonason JH, Xiao G, Zhang M, Xing L, Chen D . Post-translational regulation of Runx2 in bone and cartilage. J Dent Res 2009; 88: 693–703.
Oakley RH, Revollo J, Cidlowski JA . Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptors. Proc Natl Acad Sci USA 2012; 109: 17591–17596.
Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002; 22: 7982–7992.
Lian JB, Stein JL, Stein GS, van Wijnen AJ, Montecino M, Javed A et al. Runx2/Cbfa1 functions: diverse regulation of gene transcription by chromatin remodeling and co-regulatory protein interactions. Connect Tissue Res 2003; 44 (Suppl 1): 141–148.
Boumah CE, Lee M, Selvamurugan N, Shimizu E, Partridge NC . Runx2 recruits p300 to mediate parathyroid hormone's effects on histone acetylation and transcriptional activation of the matrix metalloproteinase-13 gene. Mol Endocrinol 2009; 23: 1255–1263.
Ali SA, Dobson JR, Lian JB, Stein JL, van Wijnen AJ, Zaidi SK et al. A RUNX2-HDAC1 co-repressor complex regulates rRNA gene expression by modulating UBF acetylation. J Cell Sci 2012; 125 (Pt 11): 2732–2739.
Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A . Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis 2013; 4: e610.
Wu H, Whitfield TW, Gordon JA, Dobson JR, Tai PW, van Wijnen AJ et al. Genomic occupancy of Runx2 with global expression profiling identifies a novel dimension to control of osteoblastogenesis. Genome Biol 2014; 15: R52.
Ge C, Xiao G, Jiang D, Franceschi RT . Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 2007; 176: 709–718.
Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, Roca H et al. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J Biol Chem 2009; 284: 32533–32543.
Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone G et al. Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease. Oncogene 2015, ;e-pub ahead of print 13 April 2015; doi:10.1038/onc.2015.91.
Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 2008; 68: 7795–7802.
Kato K, Ogura T, Kishimoto A, Minegishi Y, Nakajima N, Miyazaki M et al. Critical roles of AMP-activated protein kinase in constitutive tolerance of cancer cells to nutrient deprivation and tumor formation. Oncogene 2002; 21: 6082–6090.
Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733–741.
Zhuang Y, Miskimins WK . Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 2011; 9: 603–615.
Morales DR, Morris AD . Metformin in cancer treatment and prevention. Annu Rev Med 2015; 66: 17–29.
Dowling RJ, Goodwin PJ, Stambolic V . Understanding the benefit of metformin use in cancer treatment. BMC Med 2011; 9: 33.
Hatoum D, McGowan EM . Recent advances in the use of metformin: can treating diabetes prevent breast cancer? Biomed Res Int 2015; 2015: 548436.
Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D . LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 2009; 28: 2621–2633.
Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W et al. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Nature 2011; 477: 349–353.
Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537–549.
Campbell JP, Merkel AR, Masood-Campbell SK, Elefteriou F, Sterling JA . Models of bone metastasis. J Vis Exp 2012, e-pub ahead of print 4 September 2014; doi:10.3791/4260.
Ross RD, Edwards LH, Acerbo AS, Ominsky MS, Virdi AS, Sena K et al. Bone matrix quality after sclerostin antibody treatment. J Bone Miner Res 2014; 29: 1597–1607.
Wingender E, Kel AE, Kel OV, Karas H, Heinemeyer T, Dietze P et al. TRANSFAC, TRRD and COMPEL: towards a federated database system on transcriptional regulation. Nucleic Acids Res 1997; 25: 265–268.
Drissi H, Pouliot A, Stein JL, van Wijnen AJ, Stein GS, Lian JB . Identification of novel protein/DNA interactions within the promoter of the bone-related transcription factor Runx2/Cbfa1. J Cell Biochem 2002; 86: 403–412.
Acknowledgements
We thank Rush University Medical Center investigators; Dr Rick Sumner and his lab members, Dr Ryan Ross and Maleeha Mashiatulla for assistance with μCT data acquisition and analysis; Dr Amarjit Virdi for help with the ex vivo bone tumor co-culture model. We thank Dr Carl Maki and members of his lab, Dr Lei Duan and Ricardo Perez for helpful discussions throughout this study; Dr Elena Dedkova and Dr Lothar Blatter for assistance with sea horse data acquisition and analysis. This study was supported by the grant from Bears Care Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Tandon, M., Chen, Z., Othman, A. et al. Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis. Oncogene 35, 4730–4740 (2016). https://doi.org/10.1038/onc.2015.518
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2015.518
- Springer Nature Limited
This article is cited by
-
Itraconazole-Induced the Activation of Adenosine 5'-Monophosphate (Amp)-Activated Protein Kinase Inhibits Tumor Growth of Melanoma via Inhibiting ERK Signaling
Cell Biochemistry and Biophysics (2022)
-
RUNX2 Promotes Malignant Progression in Glioma
Neurochemical Research (2018)
-
Brain-derived neurotrophic factor promotes VEGF-C-dependent lymphangiogenesis by suppressing miR-624-3p in human chondrosarcoma cells
Cell Death & Disease (2017)